Dr. Reddy’s Laboratories\u00a0are an Indian multinational\u00a0pharmaceutical\u00a0company. The company is headquartered in Hyderabad, Telangana, India and Princeton,\u00a0New Jersey, U.S.<\/p>\n\n\n\n
\u00a0It was incorporated in 1984. The founder is Kallam Anji Reddy. The company has its operation worldwide. The products include Pharmaceuticals,\u00a0generic drugs,\u00a0over-the-counter drugs,\u00a0vaccines,\u00a0diagnostics and Biologics. The stocks are traded on NSE, BSE and the NYSE. The values are Integrity and Transparency, Safety, <\/strong>Quality, Productivity, Respect for the Individual, Collaboration and Teamwork and Sustainability.<\/strong><\/p>\n\n\n\n Dr. Reddy’s Laboratories is a pharmaceutical giant in the Indian Pharmaceutical Industry. Dr Reddy’s laboratories have 48%<\/strong> in the Indian pharmaceutical market as of financial year 2020.The main vision of this company is to provide affordable and innovative medicines for healthier lives.<\/p>\n\n\n\n Key Financial Highlights<\/u><\/strong><\/p>\n\n\n\n Revenue increased 8% Y-O-Y to Rs. 5,320 Cr.<\/p>\n\n\n\n Gross Margin is 53.8% for Q3 FY-22<\/strong><\/p>\n\n\n\n Selling, General & Administrative expenses increased 7% Y-O-Y to Rs 1541 Crs.<\/p>\n\n\n\n EBITDA is Rs 1266 Crs, 23.8% of Revenues; grew 7% YoY.<\/p>\n\n\n\n The R&D is Rs. 416 crores, i.e., USD 56 million and is at 7.8% of sales. R&D spend increased by 1% year on year basis.<\/p>\n\n\n\n Effective tax rate for the quarter is 27.2%.<\/p>\n\n\n\n Cash: The company has surplus cash balance of Rs. 998 crores. The free cash flow generated during this quarter is Rs. 1,274 crores. This has even helped the company in capital investment of Rs Rs. 414 crores.<\/p>\n\n\n\n North America<\/u><\/strong>– <\/u><\/strong>The revenue in North America isRs. 18.6 billion increased by 7%, driven by new products launches, increase in volumes of our base business and a favorable forex rate. Launched Carmustine Injection, Ephedrine Sulphate Injection, Valsartan tablets and Venlafaxine ER tablets. Filed one new ANDA during the quarter.<\/p>\n\n\n\n Europe-<\/u><\/strong>Revenues from Europe are Rs. 4.1 billion, declined by 2% due to price erosion in some of our existing products, partially offset by volume traction.<\/p>\n\n\n\n India-<\/u><\/strong>Revenue in India is 10.3 million increased 7% Y-O-Y. Sequential decline of 10%, primarily due to a reduction in sales volumes of covid-related products.<\/p>\n\n\n\n Emerging Markets- <\/u><\/strong>Revenues from Emerging Markets is Rs. 11.5 billion, increased 20% on Y-O-Y basis. Revenue from Russia is Rs. 4.7 billion, increased 5% Y-O-Y basis due to revenues from new products launched, and favourable forex rate.<\/p>\n\n\n\n Pharmaceutical Services and Active Ingredients (PSAI)-<\/u><\/strong> Year-on-year basis increased by 4%, driven majorly by new product launches. Sequential decline of 13% on account of lower volumes of certain products. Total Revenues from PSAI at Rs. 7.3 billion.<\/p>\n\n\n\n Proprietary Products (PP) & Others<\/u><\/strong>– <\/u><\/strong>Total RevenuePP & Others is Rs. 1.4 billion. There is a steep decrease of of 8% and sequential decline of 22%.<\/p>\n\n\n\n Conference Call Highlights<\/u><\/strong><\/p>\n\n\n\n Management Updates<\/u><\/strong><\/p>\n\n\n\n Reported EPS for the quarter is Rs. 42.48.<\/u><\/strong><\/p>\n\n\n\n EBITDA and RoCE margins are closer to our aspirational target of 25%.<\/p>\n\n\n\n The company is working actively with the government of India for registering Sputnik Light as a vaccine and as a booster dose of Sputnik V. <\/u><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":" Dr. Reddy’s Laboratories\u00a0are an Indian multinational\u00a0pharmaceutical\u00a0company. The company is headquartered in Hyderabad, Telangana, India and Princeton,\u00a0New Jersey, U.S. \u00a0It was incorporated in 1984. The founder is Kallam Anji Reddy. The company has its operation worldwide. The products include Pharmaceuticals,\u00a0generic drugs,\u00a0over-the-counter drugs,\u00a0vaccines,\u00a0diagnostics and Biologics. The stocks are traded on NSE, BSE and the NYSE. The values […]<\/p>\n","protected":false},"author":1796,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[6352,9908],"tags":[9138,1115],"class_list":["post-128318","post","type-post","status-publish","format-standard","hentry","category-research-summary","category-research-tear-sheet","tag-pharma","tag-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":145690,"url":"https:\/\/alphastreet.com\/india\/earnings-summary-of-dr-reddy-s-laboratories-limited-for-q4-fy23\/","url_meta":{"origin":128318,"position":0},"title":"Earnings Summary Of Dr Reddy ‘s Laboratories Limited For Q4 FY23","author":"Hardik Bhandare","date":"May 10, 2023","format":false,"excerpt":"Dr. Reddy's Laboratories Limited is an Indian multinational pharmaceutical company with a presence in over 25 countries. It was founded in 1984 and has its headquarters in Hyderabad, India. Dr. Reddy's is a research-driven company with a focus on developing and manufacturing high-quality pharmaceutical products. The company operates in three\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-9-1.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-9-1.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-9-1.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-9-1.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-9-1.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-9-1.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":143632,"url":"https:\/\/alphastreet.com\/india\/dr-reddys-laboratories-one-of-the-major-player-in-generic-segment\/","url_meta":{"origin":128318,"position":1},"title":"Dr. Reddy’s Laboratories: One Of The Major Player In Generic Segment","author":"Hardik Bhandare","date":"April 11, 2023","format":false,"excerpt":"\u201cWe are progressing well on our pipeline products. The number of filings in several of our key markets have been improving. The ANDA and DMF filings are expected to significantly improve during Q4. We are evaluating several inorganic opportunities across businesses in line with our strategy. We believe, all of\u2026","rel":"","context":"In "Research Summary"","block_context":{"text":"Research Summary","link":"https:\/\/alphastreet.com\/india\/category\/research-summary\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/04\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-1-1.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/04\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-1-1.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/04\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-1-1.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/04\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-1-1.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/04\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-1-1.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/04\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-1-1.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":142958,"url":"https:\/\/alphastreet.com\/india\/earnings-dr-reddys-laboratories-ltd-nsedrreddy-q3fy23-results-out-total-income-rise-27-yoy\/","url_meta":{"origin":128318,"position":2},"title":"Earnings | Dr. Reddy’s Laboratories Ltd. (NSE:DRREDDY): Q3FY23 Results Out; Total Income rise 27% YoY","author":"Divyansh_Kasana","date":"February 28, 2023","format":false,"excerpt":"Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY) is a multinational pharmaceutical company based in Hyderabad, India. The company was founded in 1984 and has since grown to become a leading player in the global pharmaceutical industry. Dr. Reddy's Laboratories specializes in the development, manufacturing, and marketing of generic drugs, active pharmaceutical ingredients\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":150052,"url":"https:\/\/alphastreet.com\/india\/dr-reddys-laboratories-ltd-q1fy24-18-rise-in-profits\/","url_meta":{"origin":128318,"position":3},"title":"Dr Reddy’s Laboratories Ltd Q1FY24; 18% rise in Profits.","author":"Divyansh_Kasana","date":"July 26, 2023","format":false,"excerpt":"Dr. Reddy's Laboratories Ltd is a leading India-based pharamceutical company which offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical services (CPS), generics, biosimilars and differentiated formulations. Financial Results: Dr Reddy's Laboratories Ltd reported Revenues for Q1FY24 of \u20b96,758.00 Crores up from \u20b95,233.00 Crore year\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/07\/image-268.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/07\/image-268.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/07\/image-268.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/07\/image-268.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/07\/image-268.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/07\/image-268.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":163552,"url":"https:\/\/alphastreet.com\/india\/dr-reddys-laboratories-ltd-q1fy25-1-fall-in-profits\/","url_meta":{"origin":128318,"position":4},"title":"Dr Reddy’s Laboratories Ltd Q1FY25; 1% fall in Profits","author":"Divyansh_Kasana","date":"August 2, 2024","format":false,"excerpt":"Dr. Reddy's Laboratories Ltd is a leading India-based pharamceutical company which offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical services (CPS), generics, biosimilars and differentiated formulations. Financial Results: Dr Reddy's Laboratories Ltd reported Revenues for Q1FY25 of \u20b97,696.00 Crores up from \u20b96,758.00 Crore year\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-15.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-15.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-15.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-15.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-15.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-15.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":168307,"url":"https:\/\/alphastreet.com\/india\/dr-reddys-laboratories-ltd-q4fy25-22-rise-in-profits\/","url_meta":{"origin":128318,"position":5},"title":"Dr. Reddy’s Laboratories Ltd Q4FY25; 22% rise in Profits","author":"Divyansh_Kasana","date":"May 9, 2025","format":false,"excerpt":"Company Overview: Dr. Reddy's Laboratories Ltd is a leading India-based pharmaceutical company which offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical services (CPS), generics, biosimilars and differentiated formulations. Financial Results: Dr. Reddy's Laboratories reported Total revenue for Q4FY25 of \u20b9 9,050 Crore up from\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/05\/eff747db-b47c-405d-97f0-e569811049f8.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/05\/eff747db-b47c-405d-97f0-e569811049f8.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/05\/eff747db-b47c-405d-97f0-e569811049f8.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/05\/eff747db-b47c-405d-97f0-e569811049f8.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/05\/eff747db-b47c-405d-97f0-e569811049f8.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/05\/eff747db-b47c-405d-97f0-e569811049f8.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/128318","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1796"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=128318"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/128318\/revisions"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=128318"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=128318"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=128318"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}<\/td><\/tr> <\/td><\/tr> <\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n Particulars<\/td> Q3 FY22<\/td> Q3 FY21<\/td><\/tr> Revenues<\/td> 53,197<\/td> 49,296<\/td><\/tr> Gross Profit<\/td> 28,612<\/td> 26,538<\/td><\/tr> Profit before Income Tax<\/td> 9,709<\/td> 2,843<\/td><\/tr> Profit for the period<\/td> 7,065<\/td> 198<\/td><\/tr> Diluted Earnings Per Share<\/td> 42.48<\/td> 1.19<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n